Core Insights - Carillon Tower Advisers released its third-quarter 2025 investor letter for the Carillon Eagle Mid Cap Growth Fund, highlighting a continued rally in equity markets driven by AI enthusiasm, limited inflationary effects from tariffs, and expectations for interest rate cuts from the U.S. Federal Reserve [1] - The Russell Midcap Growth Index increased by 2.78%, underperforming the Russell Midcap® Value Index, which rose by 6.16% during the same quarter [1] - The letter provided insights on various sectors including Cyclicals, Healthcare, Information Technology, Financials, and Consumer sectors, along with the fund's top 5 holdings for 2025 [1] Company Focus: Alnylam Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. is recognized for its gene-silencing technologies aimed at addressing significant unmet medical needs, with a notable product launch of vutrisiran for transthyretin (TTR) amyloidosis that exceeded sales expectations [3] - The company's stock experienced a one-month return of -8.76%, but a substantial 71.40% increase over the past 52 weeks, closing at $434.23 per share with a market capitalization of $57.368 billion as of November 24, 2025 [2] - Alnylam's product revenue grew by 103% year-over-year to $851 million in the third quarter of 2025, although it is noted that certain AI stocks may present greater upside potential with less downside risk [4]